Tiziana Life Sciences plc TLSA 深 沪
等待开盘 04-02 09:30:00 美东时间
1.25
+0.080
+6.84%
华盛通- 最 高1.306
- 今 开1.28
- 成交量 12.22万股
- 最 低 1.2102
- 昨 收 1.17
- 总市值 1.59亿
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 0.7601
- 委 比 -7.47%
- 总股本 1.27亿
- 历史最高 12.15
- 量 比 0.72
- 振 幅 8.19%
- 历史最低 0.41
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum
Tiziana Life Sciences shares jump on intranasal foralumab data, while technical indicators point to mixed momentum.
今天 01:10
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
Tiziana Life Sciences announced positive preclinical data for its intranasal foralumab, highlighting its potential to address neuroinflammation linked to aging and cognitive decline. The study showed that nasal anti-CD3 reduced neuroinflammation, enhanced neurogenesis in the hippocampus, and decreased cellular senescence. These results suggest intranasal foralumab could slow aging processes and improve cognitive function. The company is advancing...
04-01 11:00
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Wednesday after volatile sessions ear
02-25 22:39
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
Tiziana Life Sciences announced positive biomarker data from a late-breaking poster showing that nasal foralumab significantly reduced microglial activation in na-SPMS patients with PIRA, as measured by [F-18]PBR06-PET imaging. Key findings include downregulation of inflammatory CSF biomarkers (e.g., IFNAR1) and upregulation of neuroprotective proteins (e.g., MEG10), correlating with reduced microglial PET signals. These results support the poten...
02-25 12:00
Tiziana Life Sciences Prices $8M Registered Direct Offering To Management And Shareholders, Issues Warrants For Potential $9.6M Upside
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best
01-16 20:03
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences announced the closing of a registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising $8.8 million in gross proceeds. Participants also received warrants to purchase additional shares at $1.50, potentially adding up to $10.56 million. The company's CEO, Ivor Elrifi, and Executive Chairman, Gabriele Cerrone, participated significantly. Proceeds will support Phase 2 clinical trials for their lead candi...
01-16 19:45
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Tiziana Life Sciences Ltd. announced that CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The presentation will highlight Tiziana's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce neuroinflammation. The forum, organized by Sachs Associates, will also allow Tiziana's senior management to meet with i...
01-09 12:00
Tiziana Life Sciences Submits Seventh Annual Development Safety Update Report For Foralumab To FDA
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposure
2025-12-29 21:04
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana Life Sciences reported the submission of its seventh annual Development Safety Update Report (DSUR) to the FDA, highlighting the excellent safety profile of intranasal foralumab with no drug-related serious adverse events after 37.4 patient-years of cumulative exposure. The FDA's denial of Sanofi’s tolebrutinib for nrSPMS emphasizes the need for safe therapies in neuroinflammatory disorders. Tiziana's intranasal foralumab demonstrates sig...
2025-12-29 13:00
Tiziana Life Sciences withdraws proposed public offering
Tiziana Life Sciences (TLSA) announced on Monday the withdrawal of the proposed public offering of common shares due to market conditions. Tiziana Life Sciences (TLSA) shares were up 4% in premarket ...
2025-12-15 21:15
